Comparing the Availability of AQ280 in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation
Completed · Phase 1 · Has a placebo group
Conditions studied: Eosinophilic Esophagitis
In brief
This is a Phase 1, investigator- and participant-blinded, placebo-controlled, randomized, crossover study to compare bioavailability of AQ280 following single oral doses of a capsule formulation versus a tablet for oral suspension formulation in healthy participants.
Key facts
- Study ID
- NCT07093008
- Run by
- AQILION AB
- People needed
- 9
- Starts
- 2025-06-13
- Expected to finish
- 2025-07-22
- Last updated by the study team
- 2026-06-01
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.
Where it is running
- Clinical Research Site — Madison, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.